Compare Gilead Sciences, Inc. (GILD) vs Illinois Tool Works Inc. (ITW) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Gilead Sciences, Inc. vs Illinois Tool Works Inc. — how do they compare? Gilead Sciences, Inc. trades at $133.59 (market cap $163.51B), while Illinois Tool Works Inc. trades at $279.1 (market cap $78.08B). The key difference: Gilead Sciences, Inc. is far larger — about 2.1× Illinois Tool Works Inc.'s market cap, and Gilead Sciences, Inc. pays the higher dividend (2.49%). Which is the better fit depends on your goals.
| GILD | ITW | |
|---|---|---|
Market Cap | $163.51B | $78.08B |
Sector | Health | Industrials |
52-Week High | $155.80 | $299.60 |
52-Week Low | $108.22 | $241.07 |
Enterprise Value | $178.05B | $86.41B |
Dividend Yield | 2.49% | 2.37% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Gilead Sciences (GILD) trades at $130.04, down 1.04% on the day, with technical indicators showing a bearish bias while fundamentals remain strong. The company has beaten earnings expectations for three consecutive quarters, maintains robust profitability with a 30.99% net income margin, and recently secured FDA and European Commission approvals for expanded use of its oncology drug Trodelvy. Analyst consensus remains overwhelmingly positive with a $152.83 price target representing 17.5% upside potential.
The outlook for GILD is favorable with strong earnings momentum, expanding oncology portfolio, and solid cash generation, though risks include patent expirations, competitive pressures in HIV treatments, and recent negative cash flow trends. The stock presents a compelling opportunity for investors seeking exposure to a profitable biopharmaceutical company with growth catalysts, supported by Wall Street's bullish sentiment and recent regulatory wins.
Illinois Tool Works (ITW) trades at $272.28, up 0.29% on the day, with a bullish technical signal from moving averages. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.66 surpassing expectations. ITW maintains strong profitability, with a net income margin of 19.32% and ROE of 96.88%, supported by solid cash flow from operations of $3.13B in 2025. Recent news highlights segment strength and a declared dividend of $1.61 per share for Q2 2026.
ITW presents a mixed outlook with robust fundamentals and technical strength offset by valuation concerns and modest growth. The consensus price target of $288.25 implies potential upside, but high P/E and P/B ratios suggest limited margin of safety. Risks include construction sector weakness and currency headwinds. Earnings on July 28, 2026, will be critical for confirming the growth trajectory.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Gilead Sciences, Inc.
Gilead Sciences develops and markets therapies to treat life-threatening infectious diseases, with the core of its portfolio focused on HIV and hepatitis B and C. The acquisitions of Corus Pharma, Myogen, CV Therapeutics, Arresto Biosciences, and Calistoga have broadened this focus to include pulmonary and cardiovascular diseases and cancer. Gilead's acquisition of Pharmasset brought rights to hepatitis C drug Sovaldi, which is also part of combination drug Harvoni, and the Kite, Forty Seven, and Immunomedics acquisitions boost Gilead's exposure to cell therapy and noncell therapy in oncology.
Read more on GILD →About Illinois Tool Works Inc.
Illinois Tool Works is a diversified global manufacturer that produces specialized industrial equipment, consumables, and related services. The firm operates 87 global divisions through seven distinct operating segments: automotive OEM, construction products, food equipment, specialty products, test/measurement and electronics, polymers and fluids, and welding. About half of its revenue comes from its operations in North America, with the remainder originating from international markets. ITW takes a bottom-up and decentralized approach to portfolio management, with the exception that each segment must apply its 80/20 operating process modeled on the Pareto principle.
Read more on ITW →
